Filing Details
- Accession Number:
- 0001415889-24-006476
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-04 21:23:09
- Reporting Period:
- 2024-02-29
- Accepted Time:
- 2024-03-04 21:23:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1649094 | Vaxcyte Inc. | PCVX | Biological Products, (No Disgnostic Substances) (2836) | 464233385 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1813798 | Jim Wassil | C/O Vaxcyte, Inc. 825 Industrial Road, Ste. 300 San Carlos CA 94070 | Chief Operating Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-29 | 20,000 | $0.00 | 223,852 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-03-01 | 1,017 | $73.08 | 222,835 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-01 | 1,220 | $73.62 | 221,615 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-01 | 763 | $74.70 | 220,852 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-02 | 2,178 | $71.55 | 218,674 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2024-02-29 | 90,000 | $0.00 | 90,000 | $73.82 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 90,000 | 2034-02-28 | No | 4 | A | Direct |
Footnotes
- Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.355. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $74.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $74.46 to $75.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
- 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
Billionaire Hedge Funds
